A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)
Authors:
- Toshifumi YamaguchiTYToshifumi Yamaguchi
- Ryohei KawabataRKRyohei Kawabata
- Yusuke AkamaruYAYusuke Akamaru
- Hidekazu HiranoHHHidekazu Hirano
- Keijiro SugimuraKSKeijiro Sugimura
- Yasuhiro MiyazakiYMYasuhiro Miyazaki
- Yoshihiro KakejiYKYoshihiro Kakeji
- Yosuke KitoYKYosuke Kito
- Takashi NomuraTNTakashi Nomura
- Takeshi KawakamiTKTakeshi Kawakami
- Masahiro TanemuraMTMasahiro Tanemura
- Atsushi TakenoATAtsushi Takeno
Open Access
- 16 September 2026
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1349-1359
Abstract
Background: There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who experienced early recurrence during or within 6 months after DS adjuvant chemotherapy. Methods: This prospective, open-label, multicenter phase II trial enrolled eligible patients treated at 25 centers of the Osaka Gastrointestinal Cancer Chemotherapy Study Group in Japan. Patients received ramucirumab (8 mg/kg) and irinotecan (150 mg/m 2 ) every 2 weeks. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The sample size was set at 40 based on a threshold median OS of 7 months and an expected median OS of 11 months, with a one-sided alpha error of 0.05 and a power of 0.80. Results: Between November 2019 and July 2023, 43 patients were enrolled, and 39 were included in the analysis after excluding three ineligible patients and one who did not initiate protocol treatment. The median OS was 15.9 months (95% CI: 8.8–42.0; p = 0.003). The median PFS was 5.5 months (95% CI: 3.9–8.1), and the ORR was 38.5%. Grade ≥ 3 adverse events, including neutropenia (25.6%) and hypertension (25.6%), were observed in more than 20% of patients. Conclusion: Ramucirumab plus irinotecan demonstrated promising efficacy and manageable toxicity in patients with early recurrence of GC following adjuvant DS therapy. Trial registration: This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs05119071, October 6, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs051190071 ).Keywords
Funding Information
- The University of Tokyo
This publication has 32 references indexed in Scilit:
- The impact of the prognostic nutritional index (PNI) in gastric cancerLangenbeck's Archives of Surgery, 2022
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIOEuropean Journal of Cancer, 2022
- Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trialEuropean Journal of Cancer, 2020
- Japanese gastric cancer treatment guidelines 2018 (5th edition)Gastric Cancer, 2020
- Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective studyInternational Journal of Clinical Oncology, 2019
- Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxaneCancer Chemotherapy and Pharmacology, 2018
- A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trialGastric Cancer, 2018
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerJAMA Oncology, 2017
- Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701)International Journal of Clinical Oncology, 2015
- Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysisGastric Cancer, 2011